Skip to content
10-K

Annual Report

Taysha Gene Therapies, Inc. TSHA

0001193125-26-115202

← back to feed
Filed
Mar 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 19, 2026 287.27M sh
Shares Diluted FY 2025 · Dec 31, 2025 319.71M sh
Shares Diluted FY 2025 · Dec 31, 2024 250.13M sh
Capex FY 2025 · Dec 31, 2025 $738K
Capex FY 2025 · Dec 31, 2024 $374K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$93.09M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$81.23M
Long Term Debt FY 2025 · Dec 31, 2025 $50.11M
Long Term Debt FY 2025 · Dec 31, 2024 $43.94M
Cash And Equivalents FY 2025 · Dec 31, 2025 $319.77M
Cash And Equivalents FY 2025 · Dec 31, 2024 $139.04M
Stockholders Equity FY 2025 · Dec 31, 2025 $246.94M
Stockholders Equity FY 2025 · Dec 31, 2024 $71.53M
Stockholders Equity FY 2025 · Dec 31, 2023 $74.94M
Current Liabilities FY 2025 · Dec 31, 2025 $26.55M
Current Liabilities FY 2025 · Dec 31, 2024 $26.23M
Total Liabilities FY 2025 · Dec 31, 2025 $96.38M
Total Liabilities FY 2025 · Dec 31, 2024 $88.84M
Current Assets FY 2025 · Dec 31, 2025 $324.65M
Current Assets FY 2025 · Dec 31, 2024 $142.13M
Total Assets FY 2025 · Dec 31, 2025 $343.32M
Total Assets FY 2025 · Dec 31, 2024 $160.36M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.34
Eps Diluted FY 2025 · Dec 31, 2024 −$0.36
Eps Basic FY 2025 · Dec 31, 2025 −$0.34
Eps Basic FY 2025 · Dec 31, 2024 −$0.36
Sga Expense FY 2025 · Dec 31, 2025 $33.87M
Sga Expense FY 2025 · Dec 31, 2024 $28.95M
Rd Expense FY 2025 · Dec 31, 2025 $86.4M
Rd Expense FY 2025 · Dec 31, 2024 $66M
Net Income FY 2025 · Dec 31, 2025 −$109M
Net Income FY 2025 · Dec 31, 2024 −$89.3M
Operating Income FY 2025 · Dec 31, 2025 −$110.5M
Operating Income FY 2025 · Dec 31, 2024 −$91.46M
Revenue FY 2025 · Dec 31, 2025 $9.77M
Revenue FY 2025 · Dec 31, 2024 $8.33M